Last deal

$30.M

Amount

Series B

Stage

13.02.2024

Date

3

all rounds

$183.M

Total amount

General

About Company
Sudo Biosciences is a biopharmaceutical company that develops cutting-edge medications.

Industry

Sector :

Subsector :

Also Known As

Sudo

founded date

01.01.2020

Number of employees

Last funding type

Series B

IPO status

Private

Description

The company is dedicated to designing and producing innovative medicines that have no equal in their class. Their primary focus is on the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a critical mediator in cytokine signaling pathways that are associated with various immune-mediated inflammatory conditions. Sudo Biosciences is committed to transforming the lives of patients by creating best-in-class drugs that target these pathways, providing hope for people suffering from these debilitating diseases.
Contacts

Phone number

Social url